Company intelligence / Profile preview
Aardvark Therapeutics, Inc.
San Diego, California, United Statesaardvarktherapeutics.com ↗
- Ownership
- Public · AARD
- Employees
- ~22
- Development stage
- Phase 1
01
Overview
Phase 2 data for the treatment of hyperphagia associated with PWS showed multiple encouraging signals, leading to the initiation of a potentially pivotal Phase 3 HERO trial. The company completed an IPO in February 2025 with $97.9 million in gross proceeds.
- Therapeutic areas
- EndocrinologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $24.3M
- Total revenue
- $0
- Enterprise value
- $-48.9M
Beyond the preview
Go deeper on Aardvark Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aardvark Therapeutics, Inc..